Carcinoma Line Articles & Analysis
3 news found
Stockfleth were able to demonstrate that Polyphenon® E induces a concentration-dependent inhibition of cell proliferation as well as a reduction of cell vitality in four different squamous cell carcinoma cell lines (SCL-I, SCL-II, SCC-12 and SCC-13). These modifications correlate with changes in mitochondria as well as with an imbalance of cellular reactive ...
Aresus Pharma GmbH, a company of DERMAGO Holding GmbH, announced today that the abstract “Inhibition of cell-proliferation and cell viability by Polyphenon E (Veregen) in cutaneous SCC cell lines” has been accepted as an e-poster short presentation at the 31st German Skin Cancer Congress. ...
(NYSE: PFE) today announced that the US Food and Drug Administration (FDA) has approved BAVENCIO® (avelumab) in combination with axitinib for the first-line treatment of patients with advanced renal cell carcinoma (RCC). ...